ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve as a Class II director. The terms of the Class II directors will expire at the annual meeting of stockholders in 2015.
“This is a particularly exciting time to join the ACADIA board following the highly successful results from the pivotal Phase III Parkinson’s disease psychosis trial with pimavanserin,” said Dr. Biggar. “I share in ACADIA’s enthusiasm and belief that pimavanserin has the potential to transform the treatment landscape for patients suffering from this serious disorder and may also offer an improved therapy option for a broader range of neuropsychiatric disorders. Following the recent financing, which raised $86 million, ACADIA has a solid foundation for building the full potential of pimavanserin. I look forward to being a part of the ACADIA team as we work to develop and commercialize pimavanserin and other potential new drugs that may improve the lives of patients.”
Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. From April 2002 to October 2006, he served as a Principal with Baker Brothers Investments which he had joined as an Associate in April 2000. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester. Dr. Biggar also serves as a director for Synageva BioPharma Corp., a publicly traded biotechnology company.
“We are delighted that Steve has joined ACADIA’s board,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer. “His extensive experience as an investor in a wide range of biotechnology companies together with his medical and scientific training will provide our board with a unique perspective and enhance our collective experience.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV